[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605988":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":43,"locations":49,"responsibleParty":137,"collaborators":29,"id":139,"slug":140,"hasResults":141,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":29,"eligibilityCriteria":145,"healthyVolunteers":141,"sex":146,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":29,"studyType":152,"phases":153,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":52,"whyStopped":29,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Laboratoires Thea","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"T1695","EXPERIMENTAL","The participant should instill T1695.",[13,14,15,16],"Diagnostic Test: Slit Lamp Examination","Diagnostic Test: Far Best Corrected Visual Acuity (BCVA)","Drug: T1695","Diagnostic Test: Corneal fluorescein staining score on modified Oxford scale",{"label":18,"type":19,"description":20,"interventionNames":21},"Ciclosporin","ACTIVE_COMPARATOR","The participant should instill Ciclosporin.",[13,14,22,16],"Drug: Ciclosporin",[24,30,34,37,39],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DIAGNOSTIC_TEST","Slit Lamp Examination","The participant will have a slit lamp examination",[18,9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Far Best Corrected Visual Acuity (BCVA)","The participant 's BCVA will be evaluated.",[18,9],{"type":35,"name":9,"description":11,"armGroupLabels":36,"otherNames":29},"DRUG",[9],{"type":35,"name":18,"description":20,"armGroupLabels":38,"otherNames":29},[18],{"type":25,"name":40,"description":41,"armGroupLabels":42,"otherNames":29},"Corneal fluorescein staining score on modified Oxford scale","One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.",[18,9],[44],{"name":45,"role":46,"phone":47,"phoneExt":29,"email":48},"Corentin LE CAMUS","CONTACT","+33473981436","Corentin.LECAMUS@theapharma.com",[50,63,71,76,84,92,100,105,113,121,129],{"facility":51,"status":52,"city":53,"state":54,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":29},"Disha Eye Hospitals - Barrackpore","RECRUITING","Kolkata","West Bengal","India","IN",{"type":58,"coordinates":59},"Point",[60,61],88.36304,22.56263,{"lat":61,"lon":60},{"facility":64,"status":52,"city":65,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":66,"geoPoint":70,"contacts":29},"M&J Institute of Ophthalmology","Ahmedabad",{"type":58,"coordinates":67},[68,69],72.58727,23.02579,{"lat":69,"lon":68},{"facility":72,"status":52,"city":65,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":73,"geoPoint":75,"contacts":29},"Netralaya Super Speciality Eye Hospital",{"type":58,"coordinates":74},[68,69],{"lat":69,"lon":68},{"facility":77,"status":52,"city":78,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":79,"geoPoint":83,"contacts":29},"Narayana Nethralaya","Bangalore",{"type":58,"coordinates":80},[81,82],77.59369,12.97194,{"lat":82,"lon":81},{"facility":85,"status":52,"city":86,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":87,"geoPoint":91,"contacts":29},"L. V. Prasad Eye Institute (LVPEI)","Hyderabad",{"type":58,"coordinates":88},[89,90],78.45636,17.38405,{"lat":90,"lon":89},{"facility":93,"status":52,"city":94,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":95,"geoPoint":99,"contacts":29},"Agrawal Hospital","Jaipur",{"type":58,"coordinates":96},[97,98],75.78781,26.91962,{"lat":98,"lon":97},{"facility":101,"status":52,"city":53,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":102,"geoPoint":104,"contacts":29},"Regional Institute of Ophthalmology (RIO) - Kolkata",{"type":58,"coordinates":103},[60,61],{"lat":61,"lon":60},{"facility":106,"status":52,"city":107,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":108,"geoPoint":112,"contacts":29},"Regional Institute of Ophthalmology, Patna","Patna",{"type":58,"coordinates":109},[110,111],85.13563,25.59408,{"lat":111,"lon":110},{"facility":114,"status":52,"city":115,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":116,"geoPoint":120,"contacts":29},"PBMA'S H. V. Desai Eye Hospital","Pune",{"type":58,"coordinates":117},[118,119],73.85535,18.51957,{"lat":119,"lon":118},{"facility":122,"status":52,"city":123,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":124,"geoPoint":128,"contacts":29},"Shivam Retina Clinic and Eye Hospital","Surat",{"type":58,"coordinates":125},[126,127],72.83023,21.19594,{"lat":127,"lon":126},{"facility":130,"status":52,"city":131,"state":29,"zip":29,"country":55,"countryCode":56,"cosmosGeoPoint":132,"geoPoint":136,"contacts":29},"L V Prasad Eye Institute","Visakhapatnam",{"type":58,"coordinates":133},[134,135],83.20161,17.68009,{"lat":135,"lon":134},{"type":138,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100605988","phase-2-a-study-to-compare-the-effectiveness-and-safety-of-t1695-versus-ciclosporin-in-participants-with-moderate-to-severe-vernal-keratoconjunctivitis-100605988",false,"NCT07169695","A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)","Main Inclusion Criteria:\n\n* Informed consent signed and dated\n* Male or female participant from 4 years to less than 18 years old.\n* Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.\n\nMain Exclusion Criteria:\n\nParticipants must not have any conditions which might exclude them from participating, could interfere with the study, or pose an unacceptable risk to their health.","ALL","4 Years","17 Years",{"count":150,"type":151},120,"ESTIMATED","INTERVENTIONAL",[154],"PHASE2","The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis",[157],"Moderate to Severe Vernal Keratoconjunctivitis",[159],"Vernal Keratoconjunctivitis","2026-04-21",{"date":162,"type":163},"2026-04-22","ACTUAL",{"date":165,"type":163},"2026-03-24",{"date":167,"type":151},"2027-01-21",{"name":5,"class":6},11]